News
Albireo Pharma: Jubiläumstipp immer höher – wann fliegt die Decke weg?
Zu unserem zehnjährigen Jubiläum stellten wir Dir Albireo Pharma (WKN: A2DF99) als Gratis-Rakete mit einem Chance-Risiko-Verhältnis vor, wie es sonst nur in unserem exklusiven No Brainer Club (NBC)
Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat)
Recordati Rare Diseases announced today the commercial availability of Isturisa® (osilodrostat). Over 50 patients with Cushing’s syndrome have already been initiated on Isturisa® under temporary
Neueste NBC-Empfehlungen knallen +94% und +41% in wenigen Wochen
Kaum ist der neue Monat angebrochen, knallt es wieder in den NBC-Depots und die Cashberge der Mitglieder erreichen neue Allzeithochs: Mit MEI Pharma (WKN: A1KATX) und Pfenex (WKN: A118RA) schießen
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced topline results
Charles River Laboratories to Participate in Jefferies and William Blair Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2nd, at 10:00 a.m. ET, and
Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346
- ATB-346 demonstrates superiority to placebo in reducing osteoarthritis pain -
- ATB-346 is more potent than expected; lowest effective dose still to be established -
- Antibe plans
Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer
As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a preplanned efficacy and futility
Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020
Regulatory News:
NANOBIOTIX (Paris:NANO)(Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m
Clinical Response and Translational Data from DeCidE1, a Phase 2 Study of DPX-Survivac Immunotherapy in Patients with Advanced Recurrent Ovarian Cancer
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today reported
Paion, Evotec, Aurora Cannabis: 3 Perlen für 2020?
Paion (WKN: A0B65S) nähert sich der wegweisenden Marktzulassung seines Anästhetikums in den USA. Die Entscheidung fällt am 5. Juli. Die überwiegend wahrscheinliche Zulassung würde für das
QIAGEN Builds on Leading Position in Precision Medicine With Novel Solutions in Oncology
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of novel solutions enabling faster, better analysis of genomic variations in cancer – accelerating multiple
Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the National Comprehensive Cancer Network® (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to include new
Savara to Present at the Jefferies Virtual Healthcare Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at
Transgene: Combined General Meeting of May 27, 2020
Regulatory News:
The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 27, 2020) at 10:00 a.m. at the Company's headquarters (400
ICON plc to Present at Jefferies Virtual Healthcare Conference
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications
Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC
Pfizer Inc. (NYSE: PFE) today announced that it and Wyeth recommend rejection of the unsolicited tender offer made by Huguenot Bond Liquidity, LLC (“Offeror”) on May 11, 2020 (as amended and
Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to
Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that six abstracts featuring data from clinical and real-world evidence studies evaluating Rubraca® (rucaparib) in multiple tumor types have
IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced positive
Sensorion Publishes Results of General Assembly Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
NEOVACS SHARES TO RESUME TRADING ON MAY 20TH, 2020
Paris and Boston, May 19th, 2020 5:30 PM CET - Néovacs (Euronext Growth Paris: ALNEV) confirms that it has requested the resumption of trading in its shares on Euronext as soon as possible in
